Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-Authorization Safety Study of Dyston (Abobotulinum Toxin) for Glabellar Frown Lines
IRCT20150101020514N28Phase 4Completed
- Sponsor
- Imen Vaccine Alborz
- Start
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Onabotulinumtoxina + hydrogel in glabellar furrowing, sponsored by Imen Vaccine Alborz. Started Feb 2024; status: completed.
02
Drugs
Onabotulinumtoxina + hydrogel
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on IRCT20150101020514N28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150101020514N28.